Search Blog
Categories
September 2017
M T W T F S S
« Aug    
 123
45678910
11121314151617
18192021222324
252627282930  

Tags

IMPORTANT EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Top Ships Inc. and Reminds Investors with Losses to Contact the Firm

By Khang & Khang LLP

IRVINE, CA / ACCESSWIRE / September 25, 2017 / Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit against Top Ships Inc. (“Top Ships” or the “Company”) (NASDAQ: TOPS). Investors who purchased or otherwise acquired shares of Top Ships between January 17, 2017 and August 22, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm before the October 23, 2017 lead plaintiff motion deadline.

If you purchased Top Ships shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.

The Complaint alleges that CEO Evangelos J. Pistiolis (“Pistiolis”) caused Top Ships to engage in a series of manipulative share issuance/sales transactions with Kalani Investments Limited (“Kalani”) through which Top Ships would sell its common shares and securities convertible into common shares to Kalani at a significant discount to market price and file registration statements so that Kalani could resell these shares into the market. When Kalani’s sales of Top Ships stock caused the price of Top Ships stock to decline, Top Ships would reverse split the stock, causing a certain number of outstanding shares to be merged into a single share, and thereby raise the price of Top Ships stock. Then, Top Ships would again sell securities to Kalani and the same pattern of transactions would ensue.

At the same time that Top Ships was engaging in these transactions, the Company failed to disclose the true purpose of the transactions and related stock issuances and reverses – to finance related-party transactions and acquisitions that primarily benefited Pistiolis and his related companies, and otherwise funnel money to Top Ships insiders. While Top Ships used the proceeds from these offerings to further enrich Pistiolis and his affiliates through various related-party transactions, the value of Top Ships common stock has declined by more than 99%, which caused investors harm according to the Complaint.

If you wish to learn more about this lawsuit, or if you have any questions about this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for almost two decades, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in certain jurisdictions.

Contact

Joon M. Khang, Esq.

Telephone: 949-419-3834

Facsimile: 949-225-4474

joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 476227

EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Teva Pharmaceutical Industries Limited and Encourages Investors with Losses to Contact the Firm

By Khang & Khang LLP

IRVINE, CA / ACCESSWIRE / September 25, 2017 / Khang & Khang LLP (the ”Firm”) announces a securities class action lawsuit against Teva Pharmaceutical Industries Limited (”Teva” or the ”Company”) (NYSE: TEVA). Investors who purchased or otherwise acquired shares between November 15, 2016 and August 2, 2017, inclusive (the ”Class Period”), are encouraged to contact the Firm before the October 23, 2017 lead plaintiff motion deadline.

If you purchased Teva shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.

According to the Complaint, throughout the Class Period, Teva issued materially false and/or misleading statements, and/or failed to disclose, that the poor performance of its U.S. generics business resulted in the Company recording a goodwill impairment charge related to the acquisition of Actavis Generics and was a key factor in cutting Teva’s dividend by 75%. When this information was released, shares of Teva fell in value materially, which caused investors harm according to the lawsuit.

If you wish to learn more about this lawsuit, or if you have any questions regarding this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for almost two decades, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contact

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 476228

EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Rayonier Advanced Materials Inc. and Encourages Investors with Losses to Contact the Firm

By Khang & Khang LLP

IRVINE, CA / ACCESSWIRE / September 25, 2017 / Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit against Rayonier Advanced Materials Inc. (“Rayonier” or the “Company”) (NYSE: RYAM). Investors who purchased or otherwise acquired Rayonier shares from October 29, 2014 through August 19, 2015, inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the October 16, 2017 lead plaintiff motion deadline.

If you purchased Rayonier shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.

According to the Complaint, throughout the Class Period, Rayonier issued materially false and misleading statements, and/or failed to disclose adverse information. Specifically, despite the Company’s claims during the Class Period that in 2015 Rayonier “will be able to maintain or increase [its] share of volume at each of [its] top 10 customers,” since 2013, one of its top three customers, Eastman Chemical Company (“Eastman”), had been informing Rayonier of its competitors’ pricing and had requested that Rayonier respond to declines in market pricing. This led to a protracted dispute between Rayonier and Eastman over the “meet and release” provision of their agreement.

On August 18, 2015, the Company told investors that the Company filed an action against Eastman regarding its “chemical cellulose specialty products contract with Eastman.” On August 19, 2015, Rayonier issued a press release further explaining the dispute with Eastman, stating that the language in the contract at issue involved the “meet or release” provisions of the agreement, which allowed Eastman to obtain “third party offers that meet the requirements of the Supply Agreement for similar cellulose specialties products, and would require [Rayonier] to either meet such price or release the volume, thereby allowing Eastman to purchase the volume from the third party.” The release also stated that on August 12, 2017, Eastman filed an action against the Company regarding the same “meet or release” provisions in their contract. When this news was announced, shares of Rayonier fell in value materially, which caused investors harm according to the Complaint.

If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for almost two decades, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contact

Joon M. Khang, Esq.

Telephone: 949-419-3834

Facsimile: 949-225-4474

joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 476229

DEADLINE ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Forterra, Inc. and Reminds Investors with Losses to Contact the Firm

By Khang & Khang LLP

IRVINE, CA / ACCESSWIRE / September 25, 2017 / Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit against Forterra, Inc. (“Forterra” or the “Company”) (NASDAQ: FRTA). Investors, who purchased or otherwise acquired Forterra shares pursuant and/or traceable to its October 21, 2016 initial public offering (“IPO”), are encouraged to contact the Firm before October 13, 2017, the lead plaintiff motion deadline.

If you purchased Forterra shares on or about the IPO, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.

According to the Complaint, the Registration Statement which Forterra used to conduct its IPO contained false and/or misleading statements, and/or failed to disclose: that organic sales in the Company’s Drainage and Water segments declined significantly; that Forterra was experiencing increased pricing pressure due to competition and continued softness in its concrete and steel pipe business; that the Company had been losing business in its important pipe and precast business, due in large part to operational problems at its production plants; and that Forterra had undisclosed material weaknesses in its internal controls that prevented it from accurately reporting and forecasting its financial results. Since the IPO, Forterra’s stock price dropped about 75%, which harmed investors according to the Complaint.

If you wish to learn more about this lawsuit, or if you have questions about this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for almost two decades, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in certain jurisdictions.

Contact:

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 476230

DEADLINE ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Applied Optoelectronics, Inc. and Reminds Investors with Losses to Contact the Firm

By Khang & Khang LLP

IRVINE, CA / ACCESSWIRE / September 25, 2017 / Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit against Applied Optoelectronics, Inc. (“Applied Optoelectronics” or the “Company”) (NASDAQ: AAOI). Investors who purchased or otherwise acquired shares from July 13, 2017 through August 3, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm before the October 4, 2017 lead plaintiff motion deadline.

If you purchased Applied Optoelectronics shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case yet, and until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.

According to the Complaint, throughout the Class Period, Applied Optoelectronics made false and/or misleading statements and/or failed to disclose: that a major customer was decreasing its purchases of the Company’s 40G receivers; that the loss of this business would have a signfiicant negative impact on the Company’s financial performance; and that as a result of the above, the Company’s public statements were materially false and misleading at all relevant times. When this news went public, Applied Optoelectronics’ stock price fell materially, which caused investors harm according to the Complaint.

If you want to learn more about this lawsuit, or if you have any questions about this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for almost two decades, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in certain jurisdictions.

Contact

Joon M. Khang, Esq.

Telephone: 949-419-3834

Facsimile: 949-225-4474

joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 476232

APPROACHING DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Depomed, Inc. and Reminds Investors with Losses to Contact the Firm

By Khang & Khang LLP

IRVINE, CA / ACCESSWIRE / September 25, 2017 / Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit against Depomed, Inc. (“Depomed” or the “Company”) (NASDAQ: DEPO). Investors, who purchased or otherwise acquired Depomed shares from February 26, 2015 through August 7, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm before October 17, 2017, the lead plaintiff motion deadline.

If you purchased Depomed shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.

According to the Complaint, during the Class Period, Depomed made false and/or misleading statements, and/or failed to disclose: that the Company engaged in questionable practices in connection with the sales and marketing of its opioid products; that this conduct would likely subject Depomed to heightened legal and regulatory scrutiny; and that as a result of the above, the Company’s public statements were materially false and misleading at all relevant times. On August 7, 2017, Depomed announced that it “recently received a request for information from the ranking minority member of the United States Senate Committee on Homeland Security and Governmental Affairs related to the promotion of opioids” and that Depomed had also received “subpoenas related to opioid sales and marketing from the Office of the Attorney General of Maryland and the United States Department of Justice.” When this news reached the public, Depomed’s stock price dropped materially, which caused investors harm according to the Complaint.

If you wish to learn more about this lawsuit, or if you have any questions about this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for nearly two decades, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may be considered Attorney Advertising in certain jurisdictions.

Contact:

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 476233

ONE WEEK DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against The Advisory Board Company and Encourages Investors with Losses to Contact the Firm

By Khang & Khang LLP

IRVINE, CA / ACCESSWIRE / September 25, 2017 / Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit against The Advisory Board Company (“Advisory Board” or the “Company”) (NASDAQ: ABCO). Investors, who purchased or otherwise acquired shares from January 21, 2015 through February 23, 2016, inclusive (the “Class Period”), are encouraged to contact the Firm before October 2, 2017, the lead plaintiff motion deadline.

If you purchased shares of Advisory Board during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case yet, and until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.

According to the Complaint, throughout the Class Period, Advisory Board made materially false and/or misleading statements, and/or failed to disclose, that there were severe integration problems associated with its acquisition of Royall and, as a consequence of these integration problems, the Company had no basis to increase the revenue guidance for Royall during the Class Period. When this information reached the public, Advisory Board’s stock price decreased materially, which harmed investors according to the Complaint.

If you want to learn more about this lawsuit, or if you have questions about this notice or your rights, please contact Joon M. Khang, a prominent litigator for nearly two decades, by telephone at (949) 419-3834, or e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in certain jurisdictions.

Contact:

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 476234

DEADLINE UPCOMING: Khang & Khang LLP Announces Securities Class Action Lawsuit against Envision Healthcare Corporation and Encourages Investors with Losses to Contact the Firm

By Khang & Khang LLP

IRVINE, CA / ACCESSWIRE / September 25, 2017 / Khang & Khang LLP (the ”Firm”) announces a securities class action lawsuit against Envision Healthcare Corporation (”Envision” or the ”Company”) (NYSE: EVHC). Investors who purchased or otherwise acquired Envision shares from March 2, 2015 through July 21, 2017, inclusive (the ”Class Period”), are encouraged to contact the Firm before the October 3, 2017 lead plaintiff motion deadline.

If you purchased shares of Envision during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case yet, and until certification occurs, you are not represented by an attorney. You may also choose to take no action and remain a passive class member.

According to the Complaint, throughout the Class Period, Envision made materially false and/or misleading statements, and/or failed to disclose material information, to investors. On July 24, 2017, The New York Times reported that hospitals associated with the Company’s subsidiary, EmCare Holdings, Inc., were disproportionately likely to engage in ”surprise billing,” in which patients who sought treatment at in-network facilities were treated by out-of-network physicians and then billed at higher rates. When this information went public, Envision’s stock price fell materially, which harmed investors according to the Complaint.

If you wish to learn more about this lawsuit, or if you have any questions about this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for almost two decades, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in certain jurisdictions.

Contact

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 476231

IMPORTANT EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Vitamin Shoppe, Inc. and Reminds Investors with Losses to Contact the Firm

By Lundin Law PC

LOS ANGELES, CA / ACCESSWIRE / September 25, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Vitamin Shoppe, Inc. (”Vitamin Shoppe” or the ”Company”) (NYSE: VSI) for possible violations of federal securities laws from March 1, 2017 through August 6, 2017, inclusive (the ”Class Period”). Investors who purchased or otherwise acquired Vitamin Shoppe shares during the Class Period should contact the firm prior to the October 27, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here.

You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the Complaint, throughout the Class Period, Vitamin Shoppe made false and/or misleading statements, and/or failed to disclose: that the Company’s retail segment was continuing to dramatically decline; that the Company’s ongoing ”reinvention plan” had been unsuccessful and brought more than $168 million in goodwill impairment, and it was not properly recognizing that impairment charge; and that as a result of the above, the Company’s public statements were materially false and misleading at all relevant times. When this news was announced, shares of Vitamin Shoppe declined in value materially, which caused investors harm according to the Complaint.

Lundin Law PC was founded by Brian Lundin, Esq., a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethics rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 476235

DEADLINE TOMORROW: Lundin Law PC Announces Securities Class Action Lawsuit against Foundation Medicine, Inc. and Reminds Investors with Losses to Contact the Firm

By Lundin Law PC

LOS ANGELES, CA / ACCESSWIRE / September 25, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Foundation Medicine, Inc. (“Foundation” or the “Company”) (NASDAQ: FMI) for possible violations of federal securities laws from February 26, 2014 through November 3, 2015, inclusive (the “Class Period”). Investors who purchased or otherwise acquired Foundation shares during the Class Period should contact the firm by September 26, 2017, the lead plaintiff motion deadline.

To participate in this class action lawsuit, click here.

You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action yet, and until a class is certified, you are not considered to be represented by an attorney. You may also choose to do nothing and be an absent class member.

The Complaint alleges that during the Class Period, Foundation made false and/or misleading statements, and/or failed to disclose, material information to investors. On July 29, 2015, the Company disclosed that it was not making the strides obtaining coverage it claimed to have been making during the Class Period, and that Foundation would receive no Medicare payments in 2015 for its tumor profiling tests due to a delay in receiving a local coverage determination from its regional Medicare Administrative Contractor. As a result of the delay, the Company cut its 2015 financial guidance, which was based on an assumption that Medicare approval would be obtained in 2015. When this information was announced, Foundation’s stock price dropped significantly. On November 3, 2015, the Company revealed another revision to the already reduced number of clinical tests it expected to report for 2015. When this news was announced, Foundation’s stock price fell materially, which caused investors harm according to the Complaint.

Lundin Law PC was founded by Brian Lundin, Esq., a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in certain jurisdictions under the applicable law and rules of ethics.

Contact:

Lundin Law PC

Brian Lundin, Esq.

Telephone: 888-713-1033

Facsimile: 888-713-1125

brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 476236